Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Ma, Chao ^a   Xie, Jiawei ^b   Chen, Qingfeng ^b   Wang, Guoming ^b   Zuo, Shuyao ^b  

^a QINGDAO UNIVERSITY   (China)

^b Affiliated Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; RADIOACTIVE IODINE;

CANCER RADIOTHERAPY; CHILL; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG WITHDRAWAL; FLUSHING; HUMAN; HYPOCALCEMIA; HYPOTENSION; MALAISE; METALLIC TASTE; METASTASIS; REVIEW; SALIVARY GLAND SCINTISCANNING; SIDE EFFECT; SNEEZING; SOMNOLENCE; SUBTOTAL THYROIDECTOMY; TASTE DISORDER; THYROID CANCER; THYROID CARCINOMA; THYROIDECTOMY; VOMITING;

EID: 70049116644     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007956     Document Type: Review

References (73)

1. Abramson AL, Levy LM, Goodman M, Attie JN. Salivary gland scinti-scanning with technetium 99m pertechnetate. Laryngoscope 1969;79:1105-1117
2. Albrecht HH, Creutzig H. Salivary gland scintigraphy after radioiodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy. Nuklearmedizin 1976;125:546-553 (Pubitemid 8002902)
3. Allweiss P, Braunstein GD, Katz A, Waxman A. Sialadenitis following I-131 therapy for thyroid carcinoma: Concise communication. Journal of Nuclear Medicine 1984;25:755-758 (Pubitemid 14087139)
4. Anne PR. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Seminars in oncology 2002;29:80-83 (Pubitemid 36173253)
5. Baum BJ. Principles of saliva secretion. Annals of the New York Aacademy of Sciences 1993;694:17-23.
6. Becker DV, Hurley JR. Treatment of thyroid cancer with radioiodine. In: SandIer MP, Patton JA, Coleman RE, Gottschalk A, Wackers FiT, Hoffer PB editor(s). Diagnostic nuclear medicine. Baltimore: Williams & Wilkins, 1995:959-989
7. Boehme S, Wilson DB. Amifostine-induced fever: case report and review of the literature. Pharmacotherapy 2004;24:155-158 (Pubitemid 38056259)
8. Bohuslavizki KH, Brenner W, Wolf H, Sippel C, Toenshoff G, Tinnemeyer S, et al.Value of quantitative salivary gland scintigraphy in the early stage of Sjgren's syndrome. Nuclear Medicine Communications 1995;16:917-922
9. Bohuslavizki KH, Brenner W, Lassmann S, Tinnemeyer S, Toenshoff G, Sippel C, Wolf H, Clausen M, Henze E. Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. Nuclear Medicine Communications 1996;17:681-686 (Pubitemid 26289072)
10. Bohuslavizki KH, Brenner W, Lassmann S, Tinnemeyer S, Kalina S, Clausen M, et al.Quantitative salivary gland scintigraphy - a recommended examination prior to and after radioiodine therapy. Nuklearmedizin 1997;36:103-109 (Pubitemid 27186362)
11. Bohuslavizki KH, Brenner W, Klutmann S, Hubner RH, Lassmann S, Feyerabend B, et al.Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. Journal of Nuclear Medicine 1998;39:1237-1242 (Pubitemid 28326158)
12. Bohuslavizki KH, Klutmann S, Brenner W, Mester J, Henze E, Clausen M. Salivary gland protection in high-dose radioiodine treatment: Results of a double blind placebo-controlled study. Journal of Clinical Oncology 1998;16:3542-3549 (Pubitemid 28506766)
13. Bohuslavizki KH, Klutmann S, Brenner W, Kroger S, Buchert R, Bleckmann C, et al.Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Strahlentherapie und Onkologie 1999;175(Suppl 4):6-12. (Pubitemid 29084700)
14. Bohuslavizki KH, Klutmann S, Bleckmann C, Brenner W, Lassmann S, Mester J, et al.Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer. Strahlentherapie und Onkologie 1999;175:57-61. (Pubitemid 29084700)
15. Cappizi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Seminars in Oncology 1999;26:3-21.
16. Chung JK. Sodium iodide symporter: its role in nuclear medicine. Journal of Nuclear Medicine 2002;43:1188-1200.
17. Clarke SEM. Radiojodine therapy of the thyroid. In: MurrayI PC, ElI PJ editor(s). Nuclear Medicine in Clinical Diagnosis and Therapy. Edinburgh: Churchill Livingstone, 1994:833-845
18. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
19. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458-460 (Pubitemid 26039527)
20. Deeg M, Maier H, Bihl H, Adler D. Clinical picture and possible causes of functional disorders of the parotid gland in radioiodine therapy of differentiated thyroid cancer. Laryngologie, Rhinologie, Otologie 1988;67:362-366
21. Dugonji S, Ajdinovi B, Stefanovi D, Jaukovi L.Diagnostic validity of dynamic salivary gland scintigraphy with ascorbic acid stimulation in patients with Sjoegren's syndrome: comparation with unstimulated whole sialometry. Vojnosanitetski pregled 2008;65:41-46
22. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, Wingo PA, Jemal A, Feigal EG. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on the U.S. cancer burden. Cancer 2002;94:2766-2792
23. Fraker DL, Skarulis M, Livolsi V. Thyroid tumors, Cancer. Principles and practice of oncology. Lippincott, 1997.
24. Gates GA, Work WP. Radioisotope scanning of the salivary glands. Laryngoscope 1967;77:861-875
25. Haugen BR. Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation. Journal of Clinical Endocrinology and Metabolism 2004;89:3665-3667 (Pubitemid 39071452)
26. Helman J, Turner RJ, Fox PC, Baum BJ. 99mTc-pertechnetate uptake in parotid acinar cells by the Na+/K+/Cl- co-transport system. The Journal of Clinical Investigation 1987;79:1310-1313
27. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine 2002;21:1539-1558
28. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-560
29. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. The Cochrane Collaboration, available from www.cochrane-handbook.org. 2008.
30. Kim SJ, Choi HY, Kim IJ, Kim YK, Jun S, Nam HY, et al.Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan. Thyroid 2008;18:325-331
31. Koukourakis MI, Kyrias G, Kakolyris S, et al.Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. Journal of Clinical Oncology 2000;18:2226-2233 (Pubitemid 30350214)
32. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597-600.
33. Levenson D, Coulec S, Sonnenberg M, Lai E, Goldsmith SJ, Larson SM. Peripheral facial nerve palsy after high-dose radioiodine therapy in patients with papillary thyroid carcinoma. Annals of Internal Medicine 1994;120:576-578 (Pubitemid 24091599)
34. Levy O, Vieja A, Carrasco N. The Na+I- symporter (NIS): recent advances. Journal of Bioenergetics and Biomembranes 1998;30:195-206.
35. Maier H, Bihl H. Effect of radioactive iodine therapy on parotid gland function. Acta Oto-laryngologica 1987;103:318-324 (Pubitemid 17037930)
36. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003;13:265-271
37. McDonald S, Meyerowitz C, Smudzin T, et al.Preliminary results of a pilot study using WR-272t before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. International Journal of Radiation Oncology, Biology, Physics 1994;29:747-754 (Pubitemid 24241314)
38. Menard TW, Izutsu KT, Ensign WY, et al.Radioprotection by WR-2721 of gamma-irradiated rat parotid gland:effect on gland weight and secretion at 8 -10 days post irradiation. International Journal of Radiation Oncology, Biology, Physics 1984;10:1555-1559
39. Mishkin FS. Radionuclide salivary gland imaging. Seminars in Nuclear Medicine 1981;11:258-265
40. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports ofmeta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354(9193):1896- 1900.
41. Mossman KL. Frequent short-term oral complications of head and neck radiotherapy. Ear, Nose, and Throat Journal 1994;73:316-320
42. Myant NB. Iodine metabolism of salivary glands. Annals of the New York Academy of Sciences 1960;85:208-214
43. Niibe H, Takahashi I, Mitsuhashi N, et al.An evaluation of the clinical usefulness of amifostine (YM-08310) radioprotective agent. A double-blind placebo-controlled study. 1. Head and neck tumor. Nippon Gan Chiryo Gakkai Shi 1985;20:984-993 (Pubitemid 15037396)
44. Patt HM, Tyree EB, Straube RL, et al.Cystein protection against X irradiation. Science 1994;110:213-214
45. Phillips TL, Kane LJ, Utley JF. Radioprotection of tumor and normal tissues by thiophosphonate compounds. Cancer 1973;32:528-535
46. Pratt NE, Sodicoff M, Liss J, et al.Radioprotection of the rat parotid gland by WR-2721 S-2-3 aminopropylaminoethyl phosphorothioate morphology at 60 days post irradiation. International Journal of Radiation Oncology, Biology, Physics 1980;6:431-435
47. Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiotherapy and Oncology 2004;70:261-264 (Pubitemid 38520157)
48. Rasey JS, Grunbaum Z, Krohn KA, Menard TW, Spence AM. Biodistribution of the radioprotective drug S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR-77913). Radiation Research 1885;102:130-137
49. Rasey JS, Krohn KA, Grunbaum Z, et al.Synthesis, biodistribution, and autoradiography of radiolabeled S-2-(3-methylaminopropylamino)- ethylphosphorothioie acid (WR-3689). Radiation Research 1986;106:366-379 (Pubitemid 16060495)
50. Rasey JS, Grunbaum Z, Krohn KA, et al.Biodistribution of the radioprotectivedrug S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR-77913). Radiation Research 1986;102:130-137
51. Rasey JS, Spence AM, Badger CC, et al.Specific protection of different normal tissues. Pharmacology & Therapeutics 1988;39:3343.
52. Rigle RG, Scanlon PW. Radiation parotitis from radioactive iodine therapy. Proceedings of the staff meetings. Mayo Clinic 1955;30:149-153
53. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC.A systematic reviewandmeta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2004;89:3668-3676 (Pubitemid 39089119)
54. Schlumberger M, Baudin E, Travagli JP. Papillary and follicular cancers of the thyroid. Presse Medicale 1998;27:1479-1481
55. Shaw LM, Glover DJ, Turrisi A, et al.Pharmacokinetics of WR-2721. Pharmacology & Therapeutics 1988;39:195-201.
56. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, et al.Cloning of the human sodium iodide symporter. Biochemical and Biophysical Research Communications 1996;226:339-345 (Pubitemid 26331906)
57. Sodicoff M, Conger AD, Trepper P, et al.Short-term radioprotective effectsof WR-2721 on the rat parotid glands. Radiation Research 1978;76:317-326 (Pubitemid 8392318)
58. Sodicoff M, Conger AD, Pratt NE, et al.Radioprotection by WR-2721 against long-term chronic damage to the rat parotid gland. Radiation Research 1978;76:172-179 (Pubitemid 9060002)
59. Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. Journal of Clinical Endocrinology and Metabolism 1999;84:4178-4184 (Pubitemid 30648801)
60. Spitzweg C, Heufelder AE. The sodiumiodide symporter: its emerging relevance to clinical endocrinology. European Journal of Endocrinology 1998;138:374-375 (Pubitemid 28179365)
61. Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. Journal of Clinical Endocrinology and Metabolism 1999;84:4178-4184 (Pubitemid 30648801)
62. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-analysis in Context. London: BMJ Publishing Group, 2001:189-208.
63. Takahashi I, Nagai T, Miyaishi K, et al.Clinical study of the radioprotective effects of amifostine (YM-083 10. WR-272I ) on chronic radiation injury. International Journal of Radiation Oncology, Biology, Physics 1986;12:935-938 (Pubitemid 16057578)
64. Trotti A, Byhardt R, Stetz J, et al.Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. International journal of radiation oncology, biology, physics 2000;47:13-47. (Pubitemid 30179675)
65. Utley JF, Marlowe C, Waddell WJ. Distribution of 3SS-labeled WR-2721 in normal and malignant tissues of the mouse. Radiation Research 1976;68:284-291
66. Utley JF, Phillips TL, Kane LJ. Protection of normal tissues by WR-2721 during fractionated irradiation. International Journal of Radiation Oncology, Biology, Physics 1976;1:699-703.
67. Utley JF, Quinn CA, White FC, Seaver NA, Bloor CM. Protection of normal tissue against late radiation injury by WR-2721. Radiation Research 1981;85:408-415
68. Vinagre F, Santos A, Santos M, Prata A, Oliveira A, Silva JC. Salivary gland scintigraphy in the evaluation of patients with sicca complaints. Acta Reumatolìgica Portuguesa 2008;33:422-428
69. Wartofsky L. rhTSH-Stimulated Thyroglobulin Study Group Techniques in thyroidology: management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 2002;12:583-589
70. Washburn LC, Carlton JE, Hayes RL, et al.Distribution of WR-2721 in normal and malignant tissues of mice and rats bearing solid tumors: dependence on tumor type, drug dose aud species. Radiation Research 1974;59:475-483
71. Washburn LC, Sun TT, Anon JB, Hayes RL. Effect of structure on tumor specificity of alicyclic alpha-amino acids. Cancer Research 1978;38:2271-2273
72. Yuhas JM, Spellman JM, Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clinical Trials 1980;3:211-216. (Pubitemid 10010778)
73. Zidan J, Hefer E, Iosilevski G, Drumea K, Stein ME, Kuten A, et al.Efficacy of I131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer. International Journal of Radiation Oncology, Biology, Physics 2004;59:1330-1336 (Pubitemid 38954054)